An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer

Cancer Investigation

Volumn 32, Issue 6, 2014, Pages 272-284

  Xiong, Bing Hong ^a   Cheng, Yong ^a   Ma, Li ^b   Zhang, Cai Quan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Huaxi Hospital   (China)

Author keywords

Gastric cancer; Meta analysis; Neoadjuvant chemotherapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; DIARRHEA; ESOPHAGUS CANCER; FEASIBILITY STUDY; HUMAN; LEUKOPENIA; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SURGICAL MORTALITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

GASTRIC CANCER; META-ANALYSIS; NEOADJUVANT CHEMOTHERAPY; SURVIVAL;

DISEASE-FREE SURVIVAL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84902130336     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.911877     Document Type: Article

References (39)

1. Katherine DC, Alfred IN. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-363.
2. Jemal A, Bray F, Center MM, Ferlay J,Ward E, FormanD.Global cancer statistics. CA Cancer J Clin 2011;61:69-90
3. Yang L. Incidence and mortality of gastric cancer in China.World J Gastroenterol 2006;12:17-20.
4. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. N Engl JMed 1999; 340, 908-914.
5. Frei E 3rd. Clinical cancer research: an embattled species. Cancer 1982;50:1979-1992.
6. Wilke H, Preusser P, Fink U, Gunzer U, MeyerHJ, Meyer J, Siewert JR, AchterrathW, Lenaz L, Knipp H. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide,doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-1326
7. CunninghamD, AllumWH, Stenning SP, Thompson JN, Van de Velde CJ,NicolsonM, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M,Weeden S, Chua YJ,MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
8. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721.
9. Qu JJ, Shi YR, Liu FR,Ma SQ,Ma FY. A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer. ZhonghuaWei ChangWai Ke Za Zhi 2010;13:664-667.
10. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010;16:868-874.
11. Schuhmacher C, Gretschel S,Lordick F, ReichardtP,Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van CutsemE, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210-5218.
12. Hartgrink HH, van de Velde CJ, PutterH, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643-649.
13. Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study. Anticancer Res 2004;24:1879-1887.
14. Wang XL,Wu GX, Zhang MD, Guo M, ZhangH, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 2000;7:241-244.
15. Kobayashi T, Kimura T. Long-term outcome of preoperative chemotherapy with 5-deoxy-5-fluorouridine (5-DFUR) for gastric cancer. Gan To Kagaku Ryoho 2000;27:1521-1526.
16. Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stopflow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 1999;46:2035-2038.
17. KangYK, ChoiDW, ImYH, KimCM, Lee JI,MoonNM,Lee JO.A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Abstract 503 presented at the ASCO Annual Meeting. 1996. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abstdetailview&confID=29&abstractID=10042.
18. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohoyama S, Takashima T, Kimura H, Kamata T. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256-261; discussion 261-262.
19. Wu AW, Xu GW, Wang HY, Ji JF, Tang JL. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev 2007;18:CD005047.
20. He LF, Yang KH, Tian JH, Bai ZG. Meta analysis of clinical effectiveness of neoadjuvant chemotherapy for gastric cancer. Ai Zheng 2008;27:407-412.
21. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 2010;16:5621-5628.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12
23. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 (Updated September 2008). The Cochrane Collaboration 2008. Available from: http://www. cochrane-handbook.org.
24. Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, Viljanen T, Salo JA. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003;10(8):954-960.
25. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, Rohren E,Wiersema MJ, Vazquez-Sequeiros E, Murray JA, Allen MS, Levy MJ, Clain JE. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005;7(6):422-430.
26. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530-541.
27. StahlA,Ott K,WeberWA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295.
28. Matsumoto Y, Yanai H, Tokiyama H, Nishiaki M, Higaki S, Okita K. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol 2000;35:326-331.
29. Willis S, Truong S, Gribnitz S, Fass J, Schumpelick V. Endoscopic ultrasonography in the preoperative staging of gastric cancer. Surg Endosc 2000;14:951-954.
30. Polkowski M, Palucki J, Wronska E, Szawlowski A, Nasierowska-Guttmejer A, Butruk E. Endosonography versus helical computed tomography for locoregional staging of gastric cancer. Endoscopy 2004;36:617-623.
31. Meining A, Dittler HJ, Wolf A, Lorenz R, Schusdziarra V, Siewert JR, Classen M, Höfler H, Rösch T. You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 2002;50:599-603.
32. An JY, Kim HI, Cheong JH, HyungWJ, Kim CB, Noh SH. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Med J 2013;4:888-894.
33. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
34. Leong T, SmithersM, MichaelM,GebskiV,Boussioutas A, Miller D, Zalcberg JR, Wong R, Haustermans K. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG) [abstract]. J Clin Oncol 2012;30 (suppl):Abstract TPS4141. Available from: http:// abstract.asco.org/ AbstView 114 99024.html).
35. Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H, Schumacher C. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012;19(7):2108-2118.
36. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Hohenberger P, Jensen K, Kieser M, Slanger TE, GE Adenocarcinoma Meta-analysis Group. Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). J Clin Oncol 2010; 28(Suppl):4022.
37. Ectors N, Driessen A, De Hertog G, Lerut T, Geboes K. Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med 2005;129:183-185.
38. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9.
39. Gomes LI, Esteves GH, Carvalho AF, Cristo EB, Hirata R Jr,MartinsWK, Marques SM, Camargo LP, BrentaniH, Pelosof A, Zitron C, Sallum RA, Montagnini A, Soares FA, Neves EJ, Reis LF. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res 2005; 65:7127-7136.